Suchergebnisse - "Lenalidomide"

PubPharm (347)

1

Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

enthalten in: Rare tumors | 2015

von Gupta, E. | Accurso, J. | Sluzevich, J. | +2

2

Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma

enthalten in: International journal of hematology | 2015

von Totani, H. | Ri, M. | Kato, C. | +14

3

Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma

enthalten in: International journal of hematology | 2015

von Totani, H. | Ri, M. | Kato, C. | +14

4

Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma

enthalten in: International journal of hematology | 2015

von Totani, H. | Ri, M. | Kato, C. | +14

5

Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

enthalten in: Cancer medicine | 2015

von Oliva, E. | Lauseker, M. | Aloe Spiriti, M. | +14

6

Novelties in the management of B-cell malignancies : B-cell receptor signaling inhibitors and lenalidomide

enthalten in: Expert review of hematology | 2015

von Salihoglu, A. | Ar, M. | Soysal, T.

7

Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma

enthalten in: American journal of hematology | 2015

von Kumar, S. | Krishnan, A. | LaPlant, B. | +12

8

Pyoderma gangrenosum due to lenalidomide use for multiple myeloma

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2015

von Dasanu, C. | Bockorny, B. | Alexandrescu, D.

9

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines

enthalten in: Hematological oncology | 2015

von Cosenza, M. | Civallero, M. | Pozzi, S. | +3

ErratumIn: Hematol Oncol. 2016 Jun;34(2):117. - PMID 27282762

10

Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience

enthalten in: Vnitrni lekarstvi | 2015

von Jonášová, A. | Červinek, L. | Bělohlávková, P. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[35]